Claims of Killing Cancer Cells with LEDs: What the Science Does and Does Not Say
In this article
The Science Behind the Claim That LEDs ‘Destroyed 92% of Cancer Cells’
The recent social media claim that LED lights destroyed 92% of cancer cells in 30 minutes actually conflates two separate technologies— photothermal therapy using SnOx nanoflakes and light-activated antibody conjugates . This article examines where the claim originated, which studies underpin it, and its actual clinical potential.
What does this article do?
It distinguishes SnOx-based LED photothermal therapy from UEA’s light-activated antibody technology and compares the ‘miracle light therapy’ narrative with scientific evidence.
Key message:
The 92% cell death finding is real, but applies only in vitro and only to a particular skin cancer cell line. It does not mean ‘an LED treatment that destroys every type of cancer in 30 minutes.’
1. Anatomy of the Claim: Where Did It Originate and What Supports It?
Because cancer research generates considerable hope and strong emotional investment among the public, early laboratory findings are often marketed as a guarantee of clinical success . Grouping concepts such as LEDs, nanotechnology, and light activation under the same headline paved the way for two entirely different studies to be presented as ‘a single miracle treatment.’
1.1 The Texas–Porto SnOx Study: The Actual Source of 92% and 30 Minutes
The widely circulated finding of ‘92% cell death in 30 minutes’ comes from research by the University of Texas at Austin and University of Porto team on SnOx nanoflakes, published in ACS Nano.
- Mechanism: Photothermal Therapy (PTT)
- Material: Tin Oxide (SnOx) Nanoflakes
- Light Source: 810 nm Near-Infrared (NIR) LED
- Finding: In A431 skin cancer cells, after 30 minutes of LED exposure, 92% loss of viability (in vitro)
1.2 The UEA Study: Antibodies Locked in Place by Light (But Not 92%)
The University of East Anglia (UEA) team’s study, published in Nature Chemical Biology, uses an entirely different mechanism and is not the source of the 92% statistic.
- Mechanism: Photochemical conjugation (optochemical genetics)
- Material: Light-sensitive antibody fragments
- Light Source: 365 nm UV light
- Finding: Antibodies bind to tumor receptors in a covalent and permanent manner
Summary: When these two studies, which made headlines at the same time, were combined in the media under ‘light-based cancer treatment,’ they created the impression of a single ‘miracle treatment’ with the formula LED + 92% + light-activated antibodies . Scientifically, however, they are separate and complementary technologies.
2. SnOx Nanoflakes: The Biophysics of LED-Assisted Photothermal Ablation
The approach described on social media as ‘burning cancer with LEDs’ is based on the principle of Photothermal Therapy (Photothermal Therapy – PTT) . The aim is to use light to generate heat only in the target tissue and disable the cancer cell through hyperthermia .
2.1 Materials Science: Why Tin Oxide (SnOx)?
- Innovation: Instead of the gold nanoparticles used in conventional PTT, Tin Oxide (SnOx) Nanoflakes were chosen.
- Synthesis: A ‘top–down’ method involving electrochemical oxidation of tin disulfide (SnS₂) powders in an aqueous medium. Because it requires no organic solvent, it offers an advantage in green chemistry .
- Size: Thin nanoflakes approximately < 20 nm thick and < 400 nm in lateral dimensions .
- Structure: A heterogeneous mixture of SnO and SnO₂ nanocrystals, which increases light absorption and heat generation capacity.
2.2 Exciton Trapping: How Does Light Turn into Heat?
When 810 nm NIR LED light strikes SnOx nanoflakes:
- Electrons are excited to a higher energy level.
- Crystal defects and quantum size effects prevent energy from being re-emitted as light (fluorescence).
- Energy is transferred to the crystal lattice as vibrations through nonradiative relaxation .
- At the macroscopic level, these vibrations turn into heat and produce local hyperthermia.
In other words, the LED acts not only as a ‘light source’ but also like a controlled microwave oven ; however, it heats only the area containing SnOx.
2.3 Summary of In Vitro Data: Where Does 92% Apply and What Does It Mean?
| Cell Line | Cancer Type | Light Source & Duration | Change in Viability |
|---|---|---|---|
| A431 | Skin carcinoma (epidermoid) | 810 nm NIR LED, 30 minutes | 92% loss of viability |
| SW837 | Colorectal cancer | 810 nm NIR LED, 30 minutes | Approximately 50% loss of viability |
| HFF-1 | Healthy human fibroblasts | 810 nm NIR LED, 30 minutes | Negligible effect (evidence of selectivity) |
Interpretation: The most striking finding in the A431 skin cancer line is the decline of 92%. In colorectal cancer, however, effectiveness falls to around 50%; this clearly shows that generalizations such as ‘92% success for all cancers’ have no scientific basis.
3. Historical Perspective: From Photodynamic Therapy (PDT) to Photothermal Therapy (PTT)
3.1 Photodynamic Therapy (PDT): Oxygen-Dependent Light Therapy
- History: Thomas Dougherty’s work with hematoporphyrin derivatives (HPD) in the 1970s; FDA approval of Photofrin in 1993.
- Mechanism: A photosensitizing drug absorbs light, transfers the energy to tissue oxygen (O₂), and produces reactive species such as singlet oxygen that oxidize and kill the cell.
- Problem: The interiors of rapidly growing solid tumors are often hypoxic (deprived of oxygen). PDT does not work without oxygen; the most resistant tumors are also the most oxygen-deprived.
3.2 PTT: The Advantage of Targeting Oxygen-Deprived Tumors
- Key Difference: PTT is a physical rather than photochemical process; it does not need oxygen to generate heat.
- Strength of the SnOx Study: It proposes a photothermal agent that can generate heat even in oxygen-deprived environments and has the potential to penetrate the ‘hypoxic core’ .
- Academic Significance: SnOx opens ‘a new theoretical door’ to overcoming the hypoxia barrier that limits PDT; however, this door has not yet been opened clinically.
4. The UEA Approach: ‘Gluing,’ Rather Than ‘Boiling,’ with Light
The technology developed by the UEA team uses covalent chemistry rather than heat. The aim is to prevent targeted anticancer drugs, such as monoclonal antibodies, from detaching from the tumor surface.
- A synthetic, light-sensitive amino acid is incorporated into the antibody’s structure.
- When the antibody binds to the tumor receptor, it is not yet ‘locked’; equilibrium allows it to detach.
- When the area is exposed to 365 nm UV light, this artificial amino acid is activated and forms a covalent bond with the receptor, effectively ‘welding’ the antibody in place.
- This technology does not burst the cell through heat; it permanently blocks the receptor or flags it for the immune system.
Analogy: While the SnOx–LED approach attempts to ‘cook the tumor locally,’ the UEA approach attempts to secure the drug–target interaction with superglue . The two studies are different lines of research, rather than parts of the same ‘miracle treatment.’
5. Scientific Reality Check: Where Does the Urban Myth Begin?
5.1 Where Does 92% Apply?
The 92% figure was obtained in a monolayer cell culture (in vitro) :
- No blood flow → No system to dissipate heat.
- No immune system → No macrophages to clear nanoparticles.
- No tissue depth → Light reaches the cells directly.
A real tumor may not heat up as quickly because of its 3D structure and blood flow; transferring laboratory success directly into clinical practice is biophysically difficult.
5.2 Limits of Light Penetration
- UEA / UV (365 nm): It penetrates only micrometers into the skin; reaching tumors in deep organs is impossible.
- SnOx / NIR (810 nm): It lies within the ‘biological optical window’ and can penetrate tissue, but is usually limited to 1–3 cm.
For breast or intra-abdominal tumors, ‘delivering light to the tumor’ with an externally worn LED strip is unrealistic under the laws of physics. These treatments require endoscopic or surgical light-delivery devices .
5.3 Nanotoxicity and Biocompatibility
Producing SnOx nanoflakes through ‘green synthesis’ does not automatically make them safe over the long term .
- Excretion: They may be too large for renal filtration yet capable of accumulating in the liver.
- Chronic toxicity: The effects of long-term accumulation on liver/kidney function are unknown.
- Regulation: Broad clinical approval is impossible before these questions are answered.
6. Conclusion: Promising Science, Dangerous Communication
- Scientific Basis: The claim of ‘92% cancer cell death with LEDs’ is based on a serious, reputable study by the Texas–Porto team in ACS Nano ; it is not entirely fabricated.
- The Context Problem: These data apply to only a particular skin cancer cell line and an in vitro setting . Conflating them with UEA’s antibody technology creates a false myth of a ‘single treatment.’
- Clinical Reality: ‘30 minutes’ is the laboratory irradiation time, not the entire treatment process. The 92% rate cannot be generalized; effectiveness falls to around 50% in colorectal cell lines.
- Applications: Because of limitations in light penetration and toxicity, the realistic near-term applications of these technologies appear limited to superficial skin cancers, accessible head and neck lesions and clearance of the postoperative tumor bed .
- Timeline: Considering nanotoxicity, animal experiments, and Phase I–II–III processes, introducing these approaches into routine treatment requires a roadmap of 5–10 years at best .
💬 Message for clinical practice: These studies involve smart, precise opto-nanomedicine toolsdeveloped as alternatives to the ‘brute force’ of chemotherapy and radiotherapy. However, there is currently no product that can be offered to patients as a ‘miracle light therapy.’ Rather than postponing existing treatments, the safest approach is to view these technologies as research areas that warrant close attention .
Table 1. Comparison of SnOx Nanoflakes and UEA’s Light-Activated Antibodies
| Feature | SnOx Nanoflakes (Texas / Porto) | Light-Activated Antibodies (UEA) |
|---|---|---|
| Core mechanism | Photothermal: LED light is converted to heat, burning the cell. | Photochemical: UV light forms a covalent bond between the antibody and receptor. |
| Type of effect | Physical cell damage (membrane, proteins, organelles). | Biological signal blockade and permanent drug attachment to the target. |
| Type of light | Near-Infrared (810 nm) | Ultraviolet (365 nm) |
| Light penetration | 1–3 cm (varies by tissue; remains limited). | < 1 mm (essentially only superficial tissue). |
| Oxygen requirement | None; could theoretically work in the hypoxic tumor core. | Binding does not require oxygen; however, the clinical use of UV is limited. |
| Main claim | 92% cell death (in the A431 line, 30-minute LED exposure, in vitro). | Covalent, long-lasting target attachment (next-generation smart antibody design). |
Table 2. Position of SnOx-Based Photothermal Therapy in the Scientific Process (Technology Readiness Level)
| Stage | Status | Explanation |
|---|---|---|
| Basic research | Completed | Material synthesis, characterization, and photothermal properties demonstrated in the laboratory. |
| In vitro (cells) | Completed | The 92% and 50% cell death findings belong to this stage. |
| In vivo (animals) | Ongoing / uncertain | Tumor shrinkage and toxicity profiling in mouse models remain limited or at an early stage. |
| Clinical Phase I | Not started | Human safety and dose-escalation studies are required. |
| Clinical Phase II–III | Not started | There are no efficacy or long-term safety data in large patient populations yet. |
Critical reminder: While public ‘breakthrough’ language often implies Phase III evidence, the SnOx–LED photothermal approach is currently in the ‘valley of death’ between laboratory and animal research.
- New Light-Based Therapy Kills 92% of Skin Cancer Cells Without Harming Healthy Tissue.
SciTechDaily. Access - Scientists create LED light that kills cancer cells without harming healthy ones.
ScienceDaily. Access - One step closer to new light-activated cancer therapy.
Healthcare in Europe. Access - UEA scientists make breakthrough for next generation cancer treatment.
University of East Anglia (UEA). Access - LED Light Blasts Cancer Cells and Spares Healthy Ones.
UT Austin News. Access - SnOx Nanoflakes as Enhanced Near-Infrared Photothermal Therapy Agents Synthesized from Electrochemically Oxidized SnS2 Powders.
PubMed Record Page. Access - SnOx Nanoflakes as Enhanced Near-Infrared Photothermal Therapy Agents Synthesized from Electrochemically Oxidized SnS2 Powders.
ACS Nano – ACS Publications. Access - Study by FEUP and UT Austin opens new perspectives for selective and accessible cancer therapies.
Notícias U.Porto. Access - Photodynamic and Photothermal Therapies: Synergy Opportunities for Nanomedicine.
ACS Nano – Review Article. Access - Photodynamic and Photothermal Therapies: Synergy Opportunities for Nanomedicine.
PMC Full Text. Access - Publication Search (U.Porto publications relating to LEDs and photothermal therapy).
Sigarra – Universidade do Porto. Access
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.